TP53 and lymphoma: We previously identified loss of TRP53 as a factor which could confer resistance to MCL-1-targeting BH3-mimetic drugs in short-term CRISPR/Cas9 KO screens performed in Eμ-Myc mouse lymphoma cells [24].